---
title: "KAK-CIN - Reviews, Revenue and Downloads in Brazil | Apple App Store"
description: "Quick risk-calculator for contrast-induced nephropathy based on validated clinical model  KAK-CIN Score is a clinical decision-support tool designed to help healthcare professionals estimate the proba"
---

# KAK-CIN — Brazil

![KAK-CIN App Icon](https://is1-ssl.mzstatic.com/image/thumb/Purple221/v4/16/67/e7/1667e7cc-6de6-71c2-4298-227170bc180f/AppIcon-0-0-1x_U007epad-0-1-85-220.png/434x0w.png)

**Developer:** [Unknown](https://apptail.io/developer/unknown-aLmdfb)
**Category:** Medical
**Rating:** N/A (0 ratings)
**Price:** Free
**Bundle ID:** com.kakcin.kakcin2
**Store:** Apple App Store
**Country:** Brazil
**Version:** 1.0.1 (released 2025-12-09)
**Original Release:** 2025-11-24
**Languages:** English

**App Store Link:** [Download on Apple App Store](https://apps.apple.com/br/app/app/id6755145078)
**AppTail Page:** [https://apptail.io/app/kak-cin-Pfxx/brazil](https://apptail.io/app/kak-cin-Pfxx/brazil)

## KAK-CIN Description
Quick risk-calculator for contrast-induced nephropathy based on validated clinical model

KAK-CIN Score is a clinical decision-support tool designed to help healthcare professionals estimate the probability of Contrast-Induced Nephropathy (CIN) in patients who will receive intravascular contrast medium. The algorithm is based on the peer-reviewed study by Kulkarni et al (Indian Journal of Nephrology, 2023) which derived and validated a simplified risk score system. 

Key features:

Input four key patient variables:

Estimated Glomerular Filtration Rate (eGFR)
Contrast volume (mL)
Route of contrast administration (arterial vs intravenous)
Presence or absence of Diabetes Mellitus

Instantly calculates a risk-percentage for CIN and provides a risk category (e.g., low, moderate, high) and provides the CIN Score.


Published Journal:  

Why use KAK-CIN Score?

The original study included 1,300 patients (derivation 1,000 + validation 300) with an observed incidence of CIN of 3.8 %. 


The model showed high sensitivity (90.4 %) and specificity (98.8 %) in the validation cohort. 

Unlike many prior CIN risk models that were limited to cardiac catheterisation, this score covers both intra-arterial and intravenous contrast exposure. 


Important disclaimer
This app is for educational and decision-support purposes only. It does not replace clinical judgement, institutional protocols or specialist consultation. Use results in conjunction with the full clinical context. The authors are not responsible for any clinical outcomes resulting from use of this tool. Always follow local guidelines.

Privacy & Security
No patient-identifiable data is stored beyond your device.

## KAK-CIN Screenshots
- [Screenshot 1](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/bd/90/db/bd90dbd9-2612-43a4-b1ff-5fd4553376f8/img1.png/1320x2868.png)
- [Screenshot 2](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource211/v4/cc/f3/53/ccf35386-4b72-cfed-ba93-e449280aa5c6/img2.png/1320x2868.png)
- [Screenshot 3](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/3f/ad/a7/3fada7d7-47a6-d966-c972-5e1c31cc506b/img3.png/1320x2868.png)
- [Screenshot 4](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/8d/0c/cd/8d0ccded-ffa9-f1ab-592c-8c6a11fcb514/img4.png/1320x2868.png)







## KAK-CIN Available In
- [Brazil](https://apptail.io/app/kak-cin-Pfxx/brazil)
- [India](https://apptail.io/app/kak-cin-Pfxx/india)

---

## About AppTail

[AppTail](https://apptail.io) is a mobile app intelligence platform providing app analytics, ASO (App Store Optimization) tools, keyword tracking, competitor analysis, revenue estimates, and review monitoring for iOS App Store apps. Track your app's performance, discover ranking keywords, monitor competitors, and analyze market trends.

- [Search Apps](https://apptail.io)
- [Top Charts](https://apptail.io/top-iphone-apps)
- [Sign Up for Full Access](https://app.apptail.io/signup?utm_campaign=ai-crawl&utm_content=footer)

*Data provided by [AppTail](https://apptail.io) - Mobile App Intelligence Platform*